The clinical significance of the expression of CD7 antigen on the blasts of 207 consecutive patients with de novo acute myeloid leukemia (AML) was evaluated. For this purpose, fifty-three CD7+ patients (23 females and 30 males; mean age 52 years) were analyzed and classified into the following subtypes according to French-American-British (FAB) classification: 7 M0, 13 M1, 9 M2, 1 M3, 9 M4, 14 M5. Immunophenotypic studies were carried out by flow cytometry and blast cells were selected on the basis of forward light scatter gating and pan-myeloid marker, either CD 13 or CD33. All the CD7+ patients were negative for surface CD3 and T-cell-receptor (TCR) molecules. We found no correlation between CD7 expression and sex, age, hepatosplenomegaly and/or central nervous system involvement. The immaturity of CD7+ leukemic cells was supported by the high expression of CD34 (P = 0.001). CD7 positivity was significantly associated with a white blood cell count (WBC) greater than 100 × 109/L (P = 0.003). P-Glycoprotein (P-170) expression was also evaluated in 135 patients by a flow-cytometric assay: there was a close relationship between CD7 and P-170 positivity (P < 0.001). For remission induction, all patients received therapeutic regimens routinely used for AML. The complete remission (CR) rate was significantly lower in CD7+ cases (32% vs 74% P = 0.001). The overall survival and disease free survival rate of CD7+ AML was lower than those of CD7- patients (P < 0.001 and = 0.002, respectively). CD7+ AML with coexpression of CD 14 had a particularly unfavourable response and prognosis in comparison with CD7+ patients without CD14. These clinical findings in CD7+ AML subtype could be explained by the convergence of the following unfavourable prognostic factors: 1) co-expression of immaturity markers (CD34); 2) frequent monocytic differentiation (CD 14); 3) strict correlation with P-170 phenotype. These findings may require an effort to draw up a more useful diagnostic formulation of AML in clinical management. © 1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

DEL POETA, G., Stasi, R., Venditti, A., Cox, C., Aronica, G., Masi, M., et al. (1995). CD7 expression in acute myeloid leukemia. LEUKEMIA & LYMPHOMA, 17(1-2), 111-119 [10.3109/10428199509051710].

CD7 expression in acute myeloid leukemia

DEL POETA, GIOVANNI;VENDITTI, ADRIANO;BRUNO, ANTONIO;BUCCISANO, FRANCESCO;
1995-01-01

Abstract

The clinical significance of the expression of CD7 antigen on the blasts of 207 consecutive patients with de novo acute myeloid leukemia (AML) was evaluated. For this purpose, fifty-three CD7+ patients (23 females and 30 males; mean age 52 years) were analyzed and classified into the following subtypes according to French-American-British (FAB) classification: 7 M0, 13 M1, 9 M2, 1 M3, 9 M4, 14 M5. Immunophenotypic studies were carried out by flow cytometry and blast cells were selected on the basis of forward light scatter gating and pan-myeloid marker, either CD 13 or CD33. All the CD7+ patients were negative for surface CD3 and T-cell-receptor (TCR) molecules. We found no correlation between CD7 expression and sex, age, hepatosplenomegaly and/or central nervous system involvement. The immaturity of CD7+ leukemic cells was supported by the high expression of CD34 (P = 0.001). CD7 positivity was significantly associated with a white blood cell count (WBC) greater than 100 × 109/L (P = 0.003). P-Glycoprotein (P-170) expression was also evaluated in 135 patients by a flow-cytometric assay: there was a close relationship between CD7 and P-170 positivity (P < 0.001). For remission induction, all patients received therapeutic regimens routinely used for AML. The complete remission (CR) rate was significantly lower in CD7+ cases (32% vs 74% P = 0.001). The overall survival and disease free survival rate of CD7+ AML was lower than those of CD7- patients (P < 0.001 and = 0.002, respectively). CD7+ AML with coexpression of CD 14 had a particularly unfavourable response and prognosis in comparison with CD7+ patients without CD14. These clinical findings in CD7+ AML subtype could be explained by the convergence of the following unfavourable prognostic factors: 1) co-expression of immaturity markers (CD34); 2) frequent monocytic differentiation (CD 14); 3) strict correlation with P-170 phenotype. These findings may require an effort to draw up a more useful diagnostic formulation of AML in clinical management. © 1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
1995
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Con Impact Factor ISI
AML flow cytometry; CD7; Immunophenotype; Prognosis
DEL POETA, G., Stasi, R., Venditti, A., Cox, C., Aronica, G., Masi, M., et al. (1995). CD7 expression in acute myeloid leukemia. LEUKEMIA & LYMPHOMA, 17(1-2), 111-119 [10.3109/10428199509051710].
DEL POETA, G; Stasi, R; Venditti, A; Cox, C; Aronica, G; Masi, M; Bruno, A; Simone, M; Buccisano, F; Papa, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/101954
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 40
social impact